NeoAdjuvant Chemotherapy Followed by Radical Hysterectomy (OP) Versus Primary Chemo-RADiation in Cervical Cancer FIGO Stage IB2 and IIB

Launched by CHARITE UNIVERSITY, BERLIN, GERMANY · Apr 20, 2015

Keywords

ClinConnect Summary

This clinical trial is studying two different treatment approaches for women with early-stage cervical cancer, specifically those categorized as FIGO Stage IB2 and IIB. The trial compares the effectiveness of neoadjuvant chemotherapy (which is chemotherapy given before surgery) followed by a radical hysterectomy (a surgery to remove the cervix and surrounding tissues) to primary chemotherapy combined with radiation therapy. The goal is to determine which option is better for treating this type of cancer.

To participate in the trial, women must be over 18 years old and have a specific type of cervical cancer (squamous cell, adeno, or adenosquamous carcinoma). However, individuals with certain conditions, like small cell cancer, those who have had previous cancer treatment, or those who are pregnant, cannot join. While the trial is not yet recruiting participants, those who do take part can expect to receive either treatment option and will be closely monitored throughout the study to see how well the treatments work and their impact on health.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • \>18 years
• • cervical cancer FIGO IB2, IIB,
• • squamous cell, adeno or adenosquamous cell carcinoma
• • informed consent
• Exclusion Criteria:
• • small cell/neuroendocrine component
• • previous radiation, previous cancer
• • pregnancy
• • HIV
• • severe co-morbidities